Pfizer to Help Manufacture Remdesivir at Kansas Facility

Pfizer has entered into a multi-year agreement with Gilead Sciences to manufacture Gilead’s remdesivir at its facility in McPherson, Kansas.

California-based Gilead is scaling up production of the antiviral for the treatment of COVID-19, using a manufacturing network that includes more than 40 companies in North America, Europe and Asia.

Responding to concerns from advocacy groups about a possible shortage of the drug, Gilead said it will be able to make enough remdesivir to meet global demand in October.